Episode 55

This week on Biotech Hangout, hosts Daphne Zohar, Josh Schimmer, Tim Opler and Sam Fazeli discuss the latest in the biopharma industry from market updates and deals to regulatory and beyond. There were several optimistic pieces of stock news covered, including Viking Therapeutics’ strong Phase 1 obesity data and Biomea Fusion’s positive Phase 2 diabetes data. The group also discussed the positive reaction to new Phase 1b data from Biogen’s tau drug BIIB080n at International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2023), which paves the way for the drug to be another major player in the Alzheimer’s drug development space. Additionally, the hosts highlight the latest on the shortage of non-human primates for early-stage trials, Scorpion Capital’s report on Harmony Biosciences, Jounce Therapeutics’ $96.5M cash bid from Kevin Tang’s Concentra Biosciences, and more. *This episode aired on March 31, 2023* Disclosure from Josh Schimmer: "Disclosures for the companies that I cover can be found on the Biotech Hangout homepage."